PAVmed Receives 180-Day Extension To Regain Compliance With Nasdaq Minimum Bid Price Requirement
Portfolio Pulse from Happy Mohamed
PAVmed Inc., a diversified commercial-stage medical technology company, has received a 180-day extension from Nasdaq to regain compliance with its $1.00 minimum bid price requirement. The company was first notified by Nasdaq on December 29, 2022, and originally was given until June 27, 2023, to regain compliance. The new deadline is December 26, 2023. The extension has no immediate effect on the listing of the company's common stock or Series Z warrants.
June 28, 2023 | 8:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
PAVmed has been granted an extension to regain compliance with Nasdaq's minimum bid price requirement. This has no immediate effect on the company's stock or warrants.
The extension granted to PAVmed by Nasdaq allows the company more time to regain compliance with the minimum bid price requirement. This news does not have an immediate impact on the company's stock or warrants, but it does indicate that the company is working to meet Nasdaq's requirements. This could potentially influence investor sentiment and the company's stock price in the future.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100